Literature DB >> 2848463

The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis.

T Naruke1, T Goya, R Tsuchiya, K Suemasu.   

Abstract

In the past 25 years, 1,654 patients with non-small cell cancer underwent resection at National Cancer Center Hospital, Tokyo. A comparative study has been made of 5-year survival of patients who had pulmonary resection with and without mediastinal lymph node dissection. There were 426 patients (25.8% of the total) with N2 M0 disease. Of these, 345 underwent pulmonary resection with mediastinal lymph node dissection. The 5-year survival in this group was 15.9% (T1 N2 M0, 30.0%; T2 N2 M0, 14.5%; and T3 N2 M0, 12.9%). In the remaining 81 patients, who did not have mediastinal lymph node dissection, 5-year survival was 6.7%. Of the 426 patients with N2 M0 disease, 242 were select patients who underwent a curative operation with an overall 5-year survival of 19.2%. Sixty-six of them had squamous cell carcinoma and a 5-year survival of 30.8%; 153 had adenocarcinoma and a survival of 16.0%; 14 had large cell carcinoma and a survival of 12.8%; and 9 had adenosquamous cell carcinoma, and none survived 5 years. To improve the end results, it is important to perform as many curative operations with mediastinal lymph node dissection as possible. Histological cell type and tumor status must be taken into consideration.

Entities:  

Mesh:

Year:  1988        PMID: 2848463     DOI: 10.1016/s0003-4975(10)64717-0

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  43 in total

1.  [Postoperative radiotherapy in curatively resected non-small-cell bronchial carcinoma].

Authors:  H T Klages; M Stuschke
Journal:  Strahlenther Onkol       Date:  1999-03       Impact factor: 3.621

2.  The practice of cardiothoracic surgeons in the perioperative staging of non-small cell lung cancer.

Authors:  G M Tsang; D C Watson
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

3.  The practice of cardiothoracic surgeons in the perioperative staging of non-small cell lung cancer.

Authors:  P Goldstraw
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

4.  Mediastinal lymphatic drainage from pulmonary lobe based on CT observations of histoplasmosis: implications for minimal N2 disease of non-small-cell lung cancer.

Authors:  Koji Takahashi; William Stanford; Edwin Van Beek; Brad Thompson; Brian Mullan; Yutaka Sato
Journal:  Radiat Med       Date:  2007-10-26

5.  Validity of using lobe-specific regional lymph node stations to assist navigation during lymph node dissection in early stage non-small cell lung cancer patients.

Authors:  Shinichiro Miyoshi; Kazuhiko Shien; Shinichi Toyooka; Kentaroh Miyoshi; Hiromasa Yamamoto; Seiichiro Sugimoto; Junichi Soh; Makio Hayama; Masaomi Yamane; Takahiro Oto
Journal:  Surg Today       Date:  2013-10-31       Impact factor: 2.549

6.  Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study.

Authors:  Pamela M McMahon; Chung Yin Kong; Bruce E Johnson; Milton C Weinstein; Jane C Weeks; Karen M Kuntz; Jo-Anne O Shepard; Stephen J Swensen; G Scott Gazelle
Journal:  Radiology       Date:  2008-05-05       Impact factor: 11.105

7.  Has lobe-specific nodal dissection for early-stage non-small lung cancer already become standard treatment?

Authors:  Tomohiro Maniwa; Ken Kodama
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

8.  Video-assisted thoracoscopic surgery versus open lobectomy for stage I lung cancer: A meta-analysis of long-term outcomes.

Authors:  Zhengjun Li; Hongxu Liu; LE Li
Journal:  Exp Ther Med       Date:  2012-02-13       Impact factor: 2.447

Review 9.  Extended resection for higher-stage non-small-cell lung cancer.

Authors:  J D Luketich; D E van Raemdonck; R J Ginsberg
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

10.  Skip metastasis and hidden N2 disease in lung cancer: how successful is mediastinal dissection?

Authors:  N Tsubota; M Yoshimura
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.